<DrugInformationSummary id="CDR0000813149"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about quizartinib dihydrochloride
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.
  </DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/quizartinib-dihydrochloride">Quizartinib Dihydrochloride</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000547019">quizartinib dihydrochloride</TerminologyLink><GlossaryLink ref="CDR0000813206">quizartinib dihydrochloride</GlossaryLink><USBrandNames><USBrandName>Vanflyta</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>kwih-ZAR-tih-nib dy-HY-droh-KLOR-ide</TermPronunciation><MediaLink ref="CDR0000814040" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000814041" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29cdbcfe-497d-4e78-bb7b-2d4acafe8e86&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Quizartinib Dihydrochloride</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29cdbcfe-497d-4e78-bb7b-2d4acafe8e86&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Quizartinib dihydrochloride
         is approved to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000046347" dictionary="Cancer.gov" audience="Patient">Acute myeloid leukemia</GlossaryTermRef></Strong> that is newly diagnosed and has a certain <GlossaryTermRef href="CDR0000046063" dictionary="Cancer.gov" audience="Patient">mutation</GlossaryTermRef> in the <GeneName><GlossaryTermRef href="CDR0000789010" dictionary="Cancer.gov" audience="Patient">FLT3</GlossaryTermRef></GeneName> gene. It is used in adults, first with <GlossaryTermRef href="CDR0000045155" dictionary="Cancer.gov" audience="Patient">cytarabine</GlossaryTermRef> and an <GlossaryTermRef href="CDR0000044916" dictionary="Cancer.gov" audience="Patient">anthracycline</GlossaryTermRef> drug as <GlossaryTermRef href="CDR0000045736" dictionary="Cancer.gov" audience="Patient">induction therapy</GlossaryTermRef>, next with cytarabine as <GlossaryTermRef href="CDR0000045654" dictionary="Cancer.gov" audience="Patient">consolidation therapy</GlossaryTermRef>, and then alone as <GlossaryTermRef href="CDR0000045768" dictionary="Cancer.gov" audience="Patient">maintenance therapy</GlossaryTermRef>.</ListItem>
   </ItemizedList>
  <Para id="_4">Quizartinib dihydrochloride is only available as part of a special program called Vanflyta REMS (<ExternalRef xref="https://www.vanflytarems.com/#Main">Risk Evaluation and Mitigation Strategies</ExternalRef>).</Para>
 </Section><Section id="_About"><Title>More About Quizartinib Dihydrochloride</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/547019">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.26">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a623034.html">Quizartinib Dihydrochloride</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.27"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.28">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-vanflyta-aml-flt3">Quizartinib Approval Adds New Treatment Option for AML, Including in Older Patients</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C97272">Find Clinical Trials for Quizartinib Dihydrochloride</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2023-08-09</DateFirstPublished></DrugInformationSummary>
